Session

IBD (Posters)

LONG-TERM TREATMENT PERSISTENCE OF ADALIMUMAB AND USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE: A RETROSPECTIVE DATABASE STUDY
LONG-TERM TREATMENT PERSISTENCE OF ADALIMUMAB AND USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE: A RETROSPECTIVE DATABASE STUDY

IBD (Posters)  et al.

SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES
SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES

IBD (Posters)  et al.

MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN
MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN

IBD (Posters)  et al.

MESENCHYMAL STEM CELLS INJECTION INTO COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: PRELIMINARY REAL-LIFE RESULTS
MESENCHYMAL STEM CELLS INJECTION INTO COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: PRELIMINARY REAL-LIFE RESULTS

IBD (Posters)  et al.

BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

IBD (Posters)  et al.

LONG TERM SAFETY AND EFFICACY OF THIOPURINES WITHDRAWAL IN IBD PATIENTS
LONG TERM SAFETY AND EFFICACY OF THIOPURINES WITHDRAWAL IN IBD PATIENTS

IBD (Posters)  et al.

A PH-SENSITIVE OPIOID PROVIDES SUSTAINED AND SAFE PAIN RELIEF BY TARGETING THE ACIDIFIED LAYERS OF THE INFLAMED COLON
A PH-SENSITIVE OPIOID PROVIDES SUSTAINED AND SAFE PAIN RELIEF BY TARGETING THE ACIDIFIED LAYERS OF THE INFLAMED COLON

IBD (Posters)  et al.

EPIDEMIOLOGY AND CHANGES IN PHARMACOLOGIC TREATMENT OF PEDIATRIC INFLAMMATORY BOWEL DISEASE OVER 10 YEARS IN CATALONIA
EPIDEMIOLOGY AND CHANGES IN PHARMACOLOGIC TREATMENT OF PEDIATRIC INFLAMMATORY BOWEL DISEASE OVER 10 YEARS IN CATALONIA

IBD (Posters)  et al.

PROBIOTIC TREATMENT OF ULCERATIVE COLITIS WITH TRICHURIS SUIS OVA: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED CLINICAL TRIAL
PROBIOTIC TREATMENT OF ULCERATIVE COLITIS WITH TRICHURIS SUIS OVA: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED CLINICAL TRIAL

IBD (Posters)  et al.

HEPATIC STEATOSIS BUT NOT FIBROSIS IS INDEPENDENTLY ASSOCIATED WITH A POOR OUTCOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
HEPATIC STEATOSIS BUT NOT FIBROSIS IS INDEPENDENTLY ASSOCIATED WITH A POOR OUTCOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

IBD (Posters)  et al.

USE OF PLATELET-LYMPHOCYTE RATIO AND NEUTROPHIL-LYMPHOCYTE RATIO AS A POTENTIAL PROGNOSTIC MARKER IN IBD
USE OF PLATELET-LYMPHOCYTE RATIO AND NEUTROPHIL-LYMPHOCYTE RATIO AS A POTENTIAL PROGNOSTIC MARKER IN IBD

IBD (Posters)  et al.

IDENTIFICATION OF TARGET USTEKINUMAB LEVELS IN MAINTENANCE THERAPY IN INFLAMMATORY BOWEL DISEASE
IDENTIFICATION OF TARGET USTEKINUMAB LEVELS IN MAINTENANCE THERAPY IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

NEED FOR USTEKINUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE
NEED FOR USTEKINUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE

IBD (Posters)  et al.

DETECTION OF IRON RESTRICTED ERYTHROPOIESIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OVERCOMING THE INFLAMMATION TANGLER
DETECTION OF IRON RESTRICTED ERYTHROPOIESIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: OVERCOMING THE INFLAMMATION TANGLER

IBD (Posters)  et al.

RENAL INVOLVEMENT IN A COHORT OF PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE
RENAL INVOLVEMENT IN A COHORT OF PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

REAL WORLD EXPERIENCE OF USTEKINUMAB IN A WEST OF IRELAND COHORT
REAL WORLD EXPERIENCE OF USTEKINUMAB IN A WEST OF IRELAND COHORT

IBD (Posters)  et al.

A PHARMACIST-LED POST INDUCTION REVIEW CLINIC IMPROVES COMPLIANCE WITH KEY PERFORMANCE INDICATORS FOR PATIENTS NEWLY STARTED ON BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE
A PHARMACIST-LED POST INDUCTION REVIEW CLINIC IMPROVES COMPLIANCE WITH KEY PERFORMANCE INDICATORS FOR PATIENTS NEWLY STARTED ON BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

IBD (Posters)  et al.

PREDICTIVE MODEL FOR OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB THERAPY
PREDICTIVE MODEL FOR OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB THERAPY

IBD (Posters)  et al.

HIGHER ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH HISTOLOGIC REMISSION AND MUCOSAL HEALING
HIGHER ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH HISTOLOGIC REMISSION AND MUCOSAL HEALING

IBD (Posters)  et al.

Item 501 - 520 / 612
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
26
27 28 29 30 31